Marta A. Crispens

Marta A. Crispens

Auto-generated profile, based on publicly available information

Marta A. Crispens

10Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Cancer Epidemiology
Verified
Journal Article
Closed access
DHDemetra Hufnagel
Demetra Hufnagel
DKDineo Khabele
Dineo Khabele
FYFiona Yull
Fiona Yull
PHPamela C. Hull
Pamela C. Hull
JSJoellen Schildkraut
Joellen Schildkraut
ABAlicia Beeghly-Fadiel
Alicia Beeghly-Fadiel

21 January 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
Purpose: Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen with a tubulin polymerization inhibitor. We assessed the safety, activity, and pharmacokinetics of the combination AR/bevacizumab (Bev; ARB) versus weekly paclitaxel/Bev (PB) in patients with platinum-resistant/refractory HGOC (prrHGOC). Patients and Methods: Following a run-in phase I study to assess ARB safety, patients with prrHGOC with centrally confirmed MSLN-positive expression were randomized to ARB or PB (weekly paclitaxel 80 mg/m2 with Bev 10 mg/kg biweekly). Patients were stratified by platinum resistance/refractory and prior Bev. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall response rate, safety, and blood-based angiome biomarker assessment. A futility analysis was planned after 35 PFS events. Results: The combination of Bev (10 mg/kg) biweekly with AR (2.2 mg/kg) weekly was well tolerated. About phase II results, MSLN positivity was 88%, and 57 patients were randomized (28 ARB and 29 PB). Forty-two percentage of patients received prior Bev, and 23% were platinum-refractory. At futility analysis, the median PFS was 5.3 and 12.7 months for ARB and PB, respectively [P = 0.03; HR = 2.02 (1.06–3.86)]. The overall response rate was 21% with ARB and 65% with PB. The most common treatment-related grade ≥3 adverse events were anemia (18%) with ARB and neutropenia (24%) with PB. Higher baseline levels of circulating IL6 were associated with worse PFS, and its levels decreased with PB treatment. Conclusions: Our study stopped at interim analysis highlighting the benefit of PB in prrHGOC as the standard of care.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
ABAlicia Beeghly-Fadiel
Alicia Beeghly-Fadiel
SPSharon Phillips
Sharon Phillips
GBGeorge Bukenya
George Bukenya
PPPranoti Pradhan
Pranoti Pradhan
SDSara Duque
Sara Duque
MCMarta A. Crispens
Marta A. Crispens
Background: While excess adiposity is positively associated with ovarian cancer risk, the relationship with patient prognosis remains to be fully elucidated, especially with regard to changes over time during survivorship. Methods: We assembled a retrospective cohort of tumor registry confirmed ovarian, fallopian tube, and primary peritoneal cancer cases and evaluated peri- and post-diagnosis (±30 days and up to 5 years after, respectively) body mass index (BMI) from electronic medical records (EMR) from the Vanderbilt University Medical Center. Associations with overall survival (OS) were quantified by Hazards Ratios (HRs) and corresponding 95% confidence intervals (CIs) from Cox proportional hazards regression; multivariable adjustment included age, stage, grade, histologic subtype, treatment, race, and year of diagnosis. Results: We evaluated 13,676 peri- and post-diagnosis BMI observations for 616 predominantly Caucasian (87.0%) cases; the majority had serous histology (62.5%), advanced stage (58.1% Stage III or IV), high grade (52.4% poorly or undifferentiated) disease. Compared to peri-diagnosis (median =29.0), BMI was lowest 6 months post-diagnosis (median=27.4) and then gradually increased over time among survivors. In multivariable adjusted models, each 5-unit increase in mean peri-diagnosis BMI corresponded with a nonsignificant increase (HR: 1.07, 95% CI: 0.97-1.18) while higher mean post-diagnosis BMI corresponded to a significantly decreased risk of death (HR: 0.92, 95% CI: 0.84-1.00). Adjusted models that incorporated all peri- and post-diagnosis BMI observations evaluated indicated that each 5-unit increase in BMI was associated with a 15% reduced risk of death (HR: 0.85, 95% CI: 0.77-0.94). Conclusions: Whereas lower adiposity may be beneficial in terms of risk, higher adiposity appears to benefit ovarian cancer survival. Factors including cancer cachexia, weight loss among ill patients, and weight gain among survivors may contribute to this seemingly protective association. Additional research to disentangle the influence of BMI on ovarian cancer outcomes and inform adiposity guidance for ovarian cancer survivors is needed. Citation Format: Alicia Beeghly-Fadiel, Sharon Phillips, George Bukenya, Pranoti Pradhan, Sara Duque, Nneka Anyanwu, Deok-Soo Son, Andrew J. Wilson, Demetra H. Hufnagel, Marta A. Crispens. Body mass index and ovarian cancer: Changes after diagnosis and associations with overall survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3228.


17 March 2025
Verified
Other
Open access
PDF file
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
Figure S2: Figure 7: Mean ± SD concentration versus time profiles of AR (ADC), total antibody, DM4, and DM4-Me after administration of AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.

17 March 2025
Verified
Other
Open access
HAHusam A. Alqaisi
Husam A. Alqaisi
DCDavid E. Cohn
David E. Cohn
JCJing-Yi Chern
Jing-Yi Chern
LDLinda R. Duska
Linda R. Duska
AJAndrea Jewell
Andrea Jewell
SLStephanie Lheureux
Stephanie Lheureux
: Pharmacokinetic parameters of AR after administration of 2.2 mg/kg AR at 2.2 mg/kg IV x 1 plus Bev 10mg/kg IV.